Genfit S.A. (ENXTPA: GNFT)
Health Care · Biotechnology · FR
€8.40
+1.45% today · +127.0% 1Y
Genfit S.A. (ENXTPA: GNFT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $472.79M and employs 180 people.
Over the last twelve months the share price has gained 127.0%, trading between 3.40 and 15.48.
Tweenvest scores Genfit S.A. across four factors: quality 34/100, value 62/100, growth 100/100. Its strongest factor is growth.
GNFT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $472.79M
- Revenue (TTM)
- $67.96M
- P/E
- —
- EPS
- -2.04
- Dividend yield
- —
- Beta (5Y)
- 1.19
- 52-week high
- €15.48
- 52-week low
- €3.40
- Avg volume (3M)
- —
- Shares outstanding
- 50.03M
- Employees
- 180
- Next earnings
- —
About Genfit S.A.
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
- ISIN
- FR0004163111
- Founded
- 1999
- Listed since
- Dec 19, 2006
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $481.33M | HK$9.28 | -11.07% |
| Steminent Biotherapeutics Inc.TPEX: 7729 | $479.33M | NT$193.00 | +0.78% |
| Thalys Medical Technology Group CorporationSHSE: 603716 | $477.36M | CN¥14.40 | -12.57% |
| Onconic Therapeutics Inc.KOSDAQ: A476060 | $473.42M | ₩13,900.00 | -6.52% |
| Gongwin Biopharm Holdings Co., Ltd.TPEX: 6617 | $472.24M | NT$126.50 | +6.30% |
| Neurogene Inc.NasdaqGM: NGNE | $471.27M | $23.55 | -3.01% |
| Beijing Leadman Biochemistry Co.,Ltd.SZSE: 300289 | $469.93M | CN¥5.78 | -5.56% |
| Qingdao Vland Biotech INC.SHSE: 603739 | $468.53M | CN¥12.39 | -10.48% |
Figures last refreshed Oct 18, 2026.